MagForce Nanotechnologies expands management team

To support 2011 product launch and further developments

MagForce Nanotechnologies, a German specialist in nanotechnology-based cancer treatment, has expanded its management team by creating four new positions.

The Berlin-based company said these new roles will support the launch of its EU-approved therapy for the treatment of brain tumours and the further development of its Nano-Cancer therapy in additional cancer indications.

Christoph Rehfuess joins MagForce as director of intellectual property. He is a European patent attorney with 12years of experience in the biotech intellectual property field at Medigene. He takes responsibility for patents, trademarks, and technical contracts.

Dirk Kautz takes the role of director of business/corporate development. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, among others, Nihon Kohden and Biotronik.

Kajo Wiest joins as director of finance and controlling and brings with him more than 10 years of finance and controlling experience at Jerini.

Stacy Wiedenmann becomes director of investor relations and corporate communications and brings with her over 10 years of experience. She has also worked at Jerini.

The fifth new recruit is Hans Joachim Hutt, who will support the company in the area of medical affairs. The firm said his medical training and more than 20 years of experience at pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.

‘Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,’ said Peter Heinrich, ceo of MagForce.

You may also like

Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
Subscribe now